New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareOrforglipron vs ARA-290

Orforglipron vs ARA-290

Side-by-side comparison of key properties, dosing, and research.

GLP-1 / Weight Loss Agonists
Orforglipron
Immune SupportRecovery & Repair
ARA-290
Summary
Orforglipron is an oral, once-daily small-molecule GLP-1 receptor agonist developed by Eli Lilly. Unlike injectable GLP-1 peptides, it is a non-peptide compound absorbed orally without food restrictions, representing a major convenience advancement. Phase 2 trials showed up to 9.4% weight loss at 36 weeks, and Phase 3 trials (ATTAIN program) are ongoing for obesity and type 2 diabetes.
ARA-290 is a synthetic 11-amino acid peptide derived from the helix B region of erythropoietin (EPO). Unlike EPO, it selectively activates the innate repair receptor (IRR) without stimulating hematopoiesis, providing tissue protection, anti-inflammation, and neuropathy relief.
Half-Life
~12 hours (once-daily oral dosing)
~2–4 hours (SC administration)
Admin Route
Oral
SubQ
Research
Typical Dose
12 mg → 24 mg → 36 mg → 45 mg
4 mg (fixed dose)
Frequency
Once daily
Once daily
Key Benefits
  • Oral pill — no injections required
  • Once-daily dosing without food restrictions (unlike oral semaglutide)
  • Up to 9.4% body weight reduction in Phase 2 at 36 weeks
  • Significant HbA1c reduction in type 2 diabetes trials
  • Small-molecule stability — no cold chain requirements
  • Broadens access for injection-averse patients
  • Potential class-defining convenience advantage over injectable GLP-1s
  • Reduces neuropathic pain from small fiber neuropathy
  • Anti-inflammatory without immune suppression
  • Tissue protection after ischemia/reperfusion injury
  • Promotes nerve fiber regeneration
  • Improves symptoms of sarcoidosis-associated neuropathy
  • May reduce insulin resistance and improve metabolic health
  • Shown to improve autonomic neuropathy symptoms
Side Effects
  • Nausea (most common, dose-dependent)
  • Vomiting
  • Diarrhea
  • Decreased appetite
  • +2 more
  • Injection site reactions
  • Mild fatigue at initiation
  • Transient warm sensation post-injection
  • Rare: mild headache
Stacks With